Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zura Bio (ZURA)
NASDAQ:ZURA
ZURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $6.35
Previous CloseN/A
Volume136.30K
Average Volume (3M)429.88K
Market Cap
$98.59M
Enterprise Value$184.14M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 27, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding65,293,530
10 Day Avg. Volume265,965
30 Day Avg. Volume429,884
Standard Deviation0.22
R-Squared0.00
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.66
Forecast
1Y Price Target
$15.50Price Target Upside1007.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Zura Bio News
PremiumCompany Announcements
Zura Bio Highlights Strategic Goals and Clinical Advances
PremiumCompany Announcements
Zura Bio Initiates Global Phase 2 TibuSURE Study
PremiumCompany Announcements
Zura Bio to Present at Healthcare Conference
PremiumCompany Announcements
Zura Bio Announces Phase 2 Tibulizumab Study
PremiumCompany Announcements
Zura Bio Limited: Q3 2024 Financial Insights and Strategic Progress---
Bulls Say, Bears Say
Bulls Say
Market OpportunityA large unmet need for SSc patients is a therapy addressing the totality of disease, and the mechanism of tibulizumab may be well-positioned to target multiple pathways.
Regulatory ProgressThe timely launch of the Phase 2 TibuSURE trial in systemic sclerosis aligns with ZURA's stated timeline, indicating positive interactions with the FDA.
Study DesignThe thoughtfully crafted nature of the study design aims to succeed on the primary endpoint and provide derisking data for lung outcomes, potentially facilitating a move into a Phase 3 study.
Bears Say
Clinical Data ConcernsThere is a lackluster clinical data to date, with no clear dose-dependent response in B cell count reductions and an increase in IL-17A target engagement observed at the highest dose in the post-dosing follow-up period.
Strategic DecisionsLilly's decision to out-license tibulizumab to Zura after Phase 1 studies raises questions.
Uncertainty In ApprovalA 20% probability of approval is ascribed to tibulizumab in both systemic sclerosis as well as hidradenitis suppurativa, reflecting uncertainty about its success.
---
Ownership Overview
7.83% Insiders
2.85% Mutual Funds
46.12% Other Institutional Investors
38.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $1.35 and its highest was $6.35 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $98.59M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.131 by -$0.129.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.16.
How many shares outstanding does Zura Bio have?
Zura Bio has 65,293,530 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.131. Following the earnings report the stock price went up 3.953%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
---
Zura Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (1007.14% Upside)
$15.50 (1007.14% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 20.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.90%
12-Months-Change
Fundamentals
Return on Equity
-41.44%
Trailing 12-Months
Asset Growth
80.77%
Trailing 12-Months
Company Description
Zura Bio
JATT Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
---
ZURA Stock 12 Month Forecast
Average Price Target
$15.50
▲(1007.14% Upside)
Technical Analysis
Best Analysts Covering ZURA
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-50.45%
reiterated a buy rating 10 months ago
Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.45% per trade.
---